Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. source : Www.globenewswire.com save search
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.43%
H: 0.81%
C: 0.25%
therapeutics
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.18%
H: 0.4%
C: -0.14%
pharmaceuticals
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.18%
H: 0.4%
C: -0.14%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: -3.22%
H: 4.58%
C: 3.23%
medical
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.255 -17.97% -21.91% 3.2M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $7.54 -0.13% -0.13% 2.7M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.22%
H: 0.29%
C: -0.85%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -1.6%
year update financial results
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.34%
H: 3.99%
C: 3.15%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 0.91%
H: 5.05%
C: 4.9%
arv-471 fda breast cancer treatment designation
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
GNMSF | $282.004 3.83% 210
|
Health Technology
|
| O: -0.78%
H: 0.3%
C: -0.84%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.4%
H: 0.07%
C: -0.92%
GMAB | $29.42 -0.31% -0.31% 340K
|
Health Technology
|
| O: -1.21%
H: 0.72%
C: -0.11%
authorization cancer treatment application
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | $282.004 3.83% 210
|
Health Technology
|
| O: -3.69%
H: 1.71%
C: -2.41%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
GMAB | $29.42 -0.31% -0.31% 340K
|
Health Technology
|
| O: -1.1%
H: 0.46%
C: -0.06%
tivdak drug license review food cancer application
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
BNTX | $86.3 -1.81% -1.84% 780K
|
Health Technology
|
| O: -2.48%
H: 0.82%
C: -0.37%
conference
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
Published: 2023-12-14 (Crawled : 12:30) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.38%
H: 2.07%
C: -2.35%
Update: Annual Changes to the Nasdaq-100® Index
Published: 2023-12-12 (Crawled : 23:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -8.05%
H: 1.71%
C: 1.45%
TTWO 4 | $145.43 0.09% 0.09% 1.9M
|
Consumer Durables
|
| O: 2.51%
H: 1.8%
C: 1.23%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.03%
H: 0.01%
C: -0.08%
NDAQ | $60.03 -0.27% -0.27% 2.8M
|
Finance
|
| O: 0.11%
H: 4.08%
C: 3.98%
100 index
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
Published: 2023-12-08 (Crawled : 14:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $93.2 -1.28% 0.0% 1.6M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-06 (Crawled : 04:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: -1.03%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 5.35%
H: 26.96%
C: 24.13%
arv-471 conference breast symposium cancer program
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-05 (Crawled : 19:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: -1.03%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 5.35%
H: 26.96%
C: 24.13%
ibrance program trial
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.24%
H: 1.34%
C: -0.41%
vla15 disease vaccine valneva trial
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 22:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.27%
H: 1.51%
C: 1.04%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 1.72%
H: 4.07%
C: 0.6%
arv-471 breast symposium cancer
Arvinas Announces Oversubscribed $350 Million Private Placement
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: -1.98%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 2.51%
H: 11.93%
C: 7.54%
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.32%
H: 0.98%
C: 0.55%
ARVN | $33.44 -3.69% -3.83% 500K
|
Health Technology
|
| O: 1.0%
H: 4.2%
C: 4.04%
update financial results
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Published: 2023-11-07 (Crawled : 06:00) - globenewswire.com
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: -0.32%
H: 0.98%
C: 0.55%
conference valneva
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
GNMSF | $282.004 3.83% 210
|
Health Technology
|
| O: 0.24%
H: 3.29%
C: -1.11%
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.19%
H: 0.29%
C: -0.45%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
GMAB | $29.42 -0.31% -0.31% 340K
|
Health Technology
|
| O: 0.55%
H: 0.44%
C: -1.37%
BNTX | $86.3 -1.81% -1.84% 780K
|
Health Technology
|
| O: 5.74%
H: 3.18%
C: -1.55%
update financial results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.